Agrinetica leverages CRISPR 2.0 - the cutting-edge advancement beyond Nobel Prize-winning gene-editing technology - to deliver practical, high-impact traits for the $100 billion peanut industry.
While most of the world still relies on 1st-generation CRISPR systems – large, expensive, technically demanding tools that work on only a handful of crops – we’ve moved beyond their limitations.
Our platform harnesses 2nd-generation small CRISPR systems, a breakthrough class of ultra-compact, highly efficient enzymes that unlock a new era of precision editing for peanuts and other complex crops.
Traditional CRISPR systems like Cas9 were not designed for mass scale gene editing. They are large molecular machines that are difficult to deliver into plant cells and require long, costly tissue-culture steps.
Dramatically improving delivery efficiency, mainly through viral delivery
Expanding editing beyond genotype dependency, avoiding the bottlenecks of varieties that have historically been hard or impossible to modify
Shortening development cycles, removing months of labor and reducing R&D expenses
Built for real-world peanut improvement – not just research
It’s a practical, scalable platform built specifically to deliver commercially meaningful traits. Because small CRISPR systems can be deployed efficiently and without inserting foreign DNA, we can generate non-GMO, regulator-friendly peanut varieties that meet U.S. and global standards.
Combined with proprietary delivery and screening workflows, Agrinetica can produce validated gene-edited peanut lines in half the time and a fraction of the cost of 1st-generation CRISPR approaches.
